RS54775B1 - Nova disupstituisana jedinjenja 3,4-diamino-3-ciklobuten-1,2-diona za lečenje bolesti u kojima posreduju hemokini - Google Patents
Nova disupstituisana jedinjenja 3,4-diamino-3-ciklobuten-1,2-diona za lečenje bolesti u kojima posreduju hemokiniInfo
- Publication number
- RS54775B1 RS54775B1 RS20160367A RSP20160367A RS54775B1 RS 54775 B1 RS54775 B1 RS 54775B1 RS 20160367 A RS20160367 A RS 20160367A RS P20160367 A RSP20160367 A RS P20160367A RS 54775 B1 RS54775 B1 RS 54775B1
- Authority
- RS
- Serbia
- Prior art keywords
- radical
- atom
- group
- alkyl
- carbon atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
Abstract
Disupstituisano jedinjenje 3,4-diamino-3-ciklobuten-1,2-diona koje odgovara dole datoj opštoj formuli (I), ili jedna od njegovih farmaceutski prihvatljivih soli ili solvata:u kojoj:R1 predstavlja atom vodonika ili metil,R2 predstavlja prsten koji sadrži pet atoma, izabran od dole datih struktura (1), (2), (3) i (4):u kojima R5, R7a, X i X' imaju dole data značenja,R3 predstavlja aromatični ili heteroaromatični prsten izabran iz grupe koju čine prsteni koji odgovaraju donjim formulama (a) do (o):u kojima R7, R7a, Y i Z imaju dole dato značenje, pri čemu je navedeno da prsteni (a) do (o) mogu opciono imati nekoliko R7 grupa, koje mogu biti identične ili različite, ukupan najviši broj takvih R7 grupa je jedak broju atoma na prstenu koji se mogu supstituisati;R4 predstavlja aromatični ili heteroaromatični prsten izabran iz grupe koju čine prsteni koji odgovaraju dole datim formulama (p) do (z) i (aa) do (ak):u kojima R7, R8, R9, R10, R11, R12, R13, R14 i R15 imaju dole data značenja,R5 predstavlja atom vodnika, atom fluora, alkil radikal koji ima od 1 do 5 ugljenikovih atoma ili fluoroalkil ili perfluoroalkil radikal koji ima od 1 do 5 ugljenikovih atoma,R6 predstavlja atom vodonika, -COOtBu radikal ili -COOBn radikal,R7 predstavlja halogen, ili -R16, -CF3, -COR16, -OR16, -NR16R17, -NO2, -CN, -SO2R16, -SO2NR16R17, -NR16COR17, -CONR16R17, -NR16CO2R17 ili -CO2R16 radikal,R7a predstavlja atom vodonika ili alkil radikal koji ima od 1 do 5 ugljenikovih atoma,R8 predstavlja atom vodonika, atom halogena -OH radikal, ili -SH, -CONHOR16,-CONR16OH, -NR16R17, -SO3H, -OCOR16, -NHSO2R16, -SO2NR16R17, -NHCOR16, -CONR16R17, -NR16CO2R17, -NHS02NR16R17, -CO2R16, pirolil, imidazolil, triazolil ili tetrazolil radikal,R9, R10, R11 i R12 su identični ili različiti i nezavisno su izabrani iz grupe koju čine vodonik, atom halogena i alkil, alkoksi, -CF3, -OCF3, -OH, -NO2, -CN, -SO2R16, -SO2NR16R17, -NR16COR17, -NR16CO2R17, -CONR16R17, -COR16 ili -CO2R16 radikal,ili alternativno, kada dva od R9, R10, R11 i R12 radikala su u orto položaju na aromatičnom ili heteroaromatičnom prstenu izabranom iz grupe koju čine prsteni koji odgovaraju gore datim formulama (p) do (z) i (aa) do (ak), tada oni mogu zajedno obrazovati, sa vezom koja ih spaja, aril, heteroaril, cikloalkil ili heterocikloalkil prsten,R13 i R14 su identični ili različiti, izabrani iz grupe koju čine atom vodonika, atom halogena i alkil, -CF3, -OCF3, -OH, -SH, -CN, -SO2R16, -SO2NR16R17, -NHSO2NR16R17, -NR16R17, -NR16CONR16R17, -NR16COR17, -NR16CO2R17, -CONR16R17, -COR16 ili -CO2R16 radikal,R15 predstavlja atom vodonika ili -OH, -SO2R16, -COR16, -CO2R16, aril, heteroaril, arilalkil, heteroarilalkil, alkil, cikloalkil ili cikloalkilalkil radikal,R16 i R17 su identični ili različiti, izabrani iz grupe koju čine atom vodonika, jedan od sledećih radikala: aril, heteroaril, arilalkil, heteroarilalkil, alkil, fluoroalkil koji ima od 1 do 5 ugljenikovih atoma, cikloalkil ili cikloalkilalkil, i -CH2COOR18 grupa u kojoj R18 predstavlja alkil radikal koji ima od 1 do 5 ugljenikovih atoma,ili alternativno, kada se R16 i R17 nalaze na istom atomu azota, obrazuju heterocikl koji ima između 3 i 7 članova i opciono jedan ili dva heteroatoma izabrana od kiselonika, sumpora i azota pored uobičajenog atoma azota za koji su vezani, pri čemu je moguće da taj heterocikl bude supstituisan sa alkil grupom koja ima od 1 do 5 ugljenikovih atoma ili -COOR18 grupom u kojoj R18 predstavlja alkil radikal koji ima od 1 do 5 ugljenikovih atoma;X i X', koji može biti identičan ili različit, predstavlja atom kiseonika, atom sumpora ili atom azota supstituisan sa R6 radikalom,Y predstavlja atom kiseonika, atom sumpora, ili atom azota supstituisan sa R15 radikalom, iZ predstavlja ugljenikov atom ili azotov atom.Prijava sadrži još 7 patentnih zahteva.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552940P | 2011-10-28 | 2011-10-28 | |
FR1159833A FR2981935B1 (fr) | 2011-10-28 | 2011-10-28 | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
EP12791825.8A EP2771329B1 (fr) | 2011-10-28 | 2012-10-26 | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines |
PCT/FR2012/052478 WO2013061004A1 (fr) | 2011-10-28 | 2012-10-26 | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines |
Publications (1)
Publication Number | Publication Date |
---|---|
RS54775B1 true RS54775B1 (sr) | 2016-10-31 |
Family
ID=45809111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20160367A RS54775B1 (sr) | 2011-10-28 | 2012-10-26 | Nova disupstituisana jedinjenja 3,4-diamino-3-ciklobuten-1,2-diona za lečenje bolesti u kojima posreduju hemokini |
Country Status (24)
Country | Link |
---|---|
US (2) | US9388149B2 (sr) |
EP (1) | EP2771329B1 (sr) |
JP (1) | JP6068486B2 (sr) |
KR (1) | KR20140090168A (sr) |
CN (1) | CN103906738B (sr) |
AU (1) | AU2012328198A1 (sr) |
BR (1) | BR112014009889A2 (sr) |
CA (1) | CA2848263A1 (sr) |
CY (1) | CY1117705T1 (sr) |
DK (1) | DK2771329T3 (sr) |
ES (1) | ES2569053T3 (sr) |
FR (1) | FR2981935B1 (sr) |
HR (1) | HRP20160608T1 (sr) |
HU (1) | HUE029128T2 (sr) |
IN (1) | IN2014CN02273A (sr) |
MX (1) | MX342924B (sr) |
PL (1) | PL2771329T3 (sr) |
PT (1) | PT2771329E (sr) |
RS (1) | RS54775B1 (sr) |
RU (1) | RU2014121390A (sr) |
SI (1) | SI2771329T1 (sr) |
SM (1) | SMT201600151B (sr) |
WO (1) | WO2013061004A1 (sr) |
ZA (1) | ZA201401678B (sr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2930148C (en) | 2013-12-02 | 2023-04-11 | Chemocentryx, Inc. | Quinoline-8-carboxylic acid derivatives and their use to treat diseases and conditions modulated by ccr6 |
FR3030515B1 (fr) | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines |
TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Cxcr2抑制劑 |
TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
EP3668832A1 (en) | 2017-08-14 | 2020-06-24 | Allergan, Inc. | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof |
IL275839B2 (en) * | 2018-01-08 | 2024-02-01 | Chemocentryx Inc | Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist |
WO2019165315A1 (en) | 2018-02-23 | 2019-08-29 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists alone or in combination |
MX2021003318A (es) | 2018-09-21 | 2021-05-14 | Pfizer | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas utiles como inhibidores de ccr6. |
CA3177335A1 (en) | 2020-04-30 | 2021-11-04 | Oliver Allemann | Azetidin-3-ylmethanol derivatives as ccr6 receptor modulators |
WO2023057548A1 (en) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
WO2023072924A1 (en) | 2021-10-26 | 2023-05-04 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
EP4423075A1 (en) | 2021-10-28 | 2024-09-04 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6652737B2 (en) * | 2000-07-21 | 2003-11-25 | Exxonmobil Research And Engineering Company | Production of naphtha and light olefins |
DK1381590T3 (da) * | 2001-04-16 | 2007-10-22 | Schering Corp | 3,4-disubstituerede cyclobuten-1,2-dioner som CXC-kemokinreceptorligander |
ATE554066T1 (de) * | 2007-06-06 | 2012-05-15 | Novartis Ag | Entzündungshemmende substituierte cyclobutendionverbindungen |
UA103198C2 (en) * | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
KR200444641Y1 (ko) * | 2008-12-03 | 2009-05-27 | 강민수 | 헤드작동형 다기능 스패너 |
WO2010063802A1 (en) * | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
WO2010131145A1 (en) * | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
-
2011
- 2011-10-28 FR FR1159833A patent/FR2981935B1/fr not_active Expired - Fee Related
-
2012
- 2012-10-26 ES ES12791825.8T patent/ES2569053T3/es active Active
- 2012-10-26 KR KR1020147011443A patent/KR20140090168A/ko not_active Application Discontinuation
- 2012-10-26 SI SI201230577A patent/SI2771329T1/sl unknown
- 2012-10-26 CA CA2848263A patent/CA2848263A1/fr not_active Abandoned
- 2012-10-26 PL PL12791825.8T patent/PL2771329T3/pl unknown
- 2012-10-26 RU RU2014121390/04A patent/RU2014121390A/ru not_active Application Discontinuation
- 2012-10-26 BR BR112014009889A patent/BR112014009889A2/pt not_active IP Right Cessation
- 2012-10-26 IN IN2273CHN2014 patent/IN2014CN02273A/en unknown
- 2012-10-26 EP EP12791825.8A patent/EP2771329B1/fr active Active
- 2012-10-26 RS RS20160367A patent/RS54775B1/sr unknown
- 2012-10-26 AU AU2012328198A patent/AU2012328198A1/en not_active Abandoned
- 2012-10-26 US US14/354,033 patent/US9388149B2/en not_active Expired - Fee Related
- 2012-10-26 PT PT127918258T patent/PT2771329E/pt unknown
- 2012-10-26 MX MX2014003958A patent/MX342924B/es active IP Right Grant
- 2012-10-26 WO PCT/FR2012/052478 patent/WO2013061004A1/fr active Application Filing
- 2012-10-26 CN CN201280052911.8A patent/CN103906738B/zh not_active Expired - Fee Related
- 2012-10-26 DK DK12791825.8T patent/DK2771329T3/en active
- 2012-10-26 JP JP2014537704A patent/JP6068486B2/ja not_active Expired - Fee Related
- 2012-10-26 HU HUE12791825A patent/HUE029128T2/en unknown
-
2014
- 2014-03-06 ZA ZA2014/01678A patent/ZA201401678B/en unknown
-
2016
- 2016-05-31 SM SM201600151T patent/SMT201600151B/it unknown
- 2016-06-02 CY CY20161100489T patent/CY1117705T1/el unknown
- 2016-06-06 HR HRP20160608TT patent/HRP20160608T1/hr unknown
- 2016-06-07 US US15/175,363 patent/US9580412B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103906738A (zh) | 2014-07-02 |
FR2981935B1 (fr) | 2015-08-07 |
SMT201600151B (it) | 2016-07-01 |
US20140296254A1 (en) | 2014-10-02 |
FR2981935A1 (fr) | 2013-05-03 |
CY1117705T1 (el) | 2017-05-17 |
JP6068486B2 (ja) | 2017-01-25 |
MX2014003958A (es) | 2014-08-27 |
PT2771329E (pt) | 2016-06-17 |
AU2012328198A1 (en) | 2014-04-03 |
EP2771329B1 (fr) | 2016-03-16 |
HRP20160608T1 (hr) | 2016-07-01 |
DK2771329T3 (en) | 2016-06-06 |
US9580412B2 (en) | 2017-02-28 |
WO2013061004A8 (fr) | 2014-04-17 |
JP2014530894A (ja) | 2014-11-20 |
MX342924B (es) | 2016-10-19 |
EP2771329A1 (fr) | 2014-09-03 |
IN2014CN02273A (sr) | 2015-06-19 |
KR20140090168A (ko) | 2014-07-16 |
BR112014009889A2 (pt) | 2017-04-25 |
ZA201401678B (en) | 2015-04-29 |
RU2014121390A (ru) | 2015-12-10 |
SI2771329T1 (sl) | 2016-07-29 |
HUE029128T2 (en) | 2017-02-28 |
PL2771329T3 (pl) | 2016-09-30 |
US9388149B2 (en) | 2016-07-12 |
ES2569053T3 (es) | 2016-05-06 |
CN103906738B (zh) | 2016-09-07 |
US20160362403A1 (en) | 2016-12-15 |
CA2848263A1 (fr) | 2013-05-02 |
WO2013061004A1 (fr) | 2013-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS54775B1 (sr) | Nova disupstituisana jedinjenja 3,4-diamino-3-ciklobuten-1,2-diona za lečenje bolesti u kojima posreduju hemokini | |
NO20074071L (no) | Hydrazinometyl, hydrozonometyl og 5-leddete heterocykliske forbindelser som virker som MTOR inhibitorer og anvendelse derav som anti-cancer midler | |
RS54702B1 (sr) | Pirazolohinolinski derivati kao inhibitori pde9 | |
RS54708B1 (sr) | Ariletinil derivati | |
RS53939B1 (sr) | Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora | |
NO20053600L (no) | Pyrazolo (3,4-b)pyridinforbindelser og anvendelse derav som fosfodiesterase inhibitorer. | |
JP2016506369A5 (sr) | ||
MX2010003445A (es) | Derivados de nicotinamida, su preparacion y su uso terapeutico. | |
RS50552B (sr) | Derivati pirolopiridina i njihova upotreba kao antagonista crth2 | |
RS54175B1 (sr) | Inhibitori bromodomena i njihova primena | |
JP2013509442A5 (sr) | ||
CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
RS52261B (sr) | Amidofenoksi indazoli kao korisni inhibitori c-met-a | |
MX2016006685A (es) | Compuestos heterociclicos de n-acilimino. | |
EA201390022A8 (ru) | Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ) | |
EA201170099A1 (ru) | Замещенные пиримидин-4-оновые производные | |
EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
AR059901A1 (es) | Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares. | |
EA201171000A1 (ru) | Производные азаспиранилалкилкарбаматов в форме 5-членных гетероциклов, способ их получения и применение в терапии | |
AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
RS53378B (sr) | Jedinjenja sa kondenzovanim prstenom i njihova upotreba | |
HRP20110785T8 (en) | Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands | |
HRP20070498T3 (en) | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | |
AR088816A1 (es) | Proceso para preparar derivados de 1-acil-4-fenilsulfonilprolinamida y compuestos intermediarios |